Haploidentical Hematopoietic Stem Cell Transplantation Using A Novel Clofarabine Containing Conditioning Regimen For Patients With Refractory Hematologic Malignancies

Trial Profile

Haploidentical Hematopoietic Stem Cell Transplantation Using A Novel Clofarabine Containing Conditioning Regimen For Patients With Refractory Hematologic Malignancies

Completed
Phase of Trial: Phase I

Latest Information Update: 06 Jan 2017

At a glance

  • Drugs Clofarabine (Primary) ; Granulocyte colony-stimulating factors; Granulocyte colony-stimulating factors; Melphalan; Muromonab CD3; Mycophenolate mofetil; Rituximab; Thiotepa
  • Indications Acute lymphoblastic leukaemia; Acute myeloid leukaemia; Chronic myeloid leukaemia; Graft-versus-host disease; Haematological malignancies; Hodgkin's disease; Juvenile myelomonocytic leukaemia; Myelodysplastic syndromes; Non-Hodgkin's lymphoma
  • Focus Adverse reactions
  • Acronyms REFLEX
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 30 Dec 2016 Status changed from active, no longer recruiting to completed.
    • 29 Nov 2016 Planned End Date changed from 1 Nov 2016 to 1 Dec 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top